MONROVIA, Calif. , Jan. 7, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that the National Institutes of Health

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Martinsried/Munich, Germany, and Monrovia, Calif. – June 28, 2010 – MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based biopharmaceutical company Xencor, Inc., announced today the

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical

Results Show Durable Responses in High Risk Patient Population

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 (XmAb5574) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and US-based Xencor, Inc. today announced completion of the phase 1/2a clinical trial evaluating MOR208 (formerly XmAb®5574) in patients with

Martinsried/Munich, Germany, and Monrovia, Calif., USA, May 22, 2012—MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia MONROVIA, Calif., April 26, 2013 – Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic

MedImmune Licenses Xencor’s XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year Monrovia, CA – December 7, 2005 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has

Proprietary tool to assess potential protein immunogenicity for 95% of U.S. population.

Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced the appointment of Jeffrey D. Bloss, M.D., F.A.C.O.G., as chief medical officer. Dr.